Navigation Links
Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
Date:7/28/2008

Financing will advance the company's clinical development programs and

CombiPlex(TM) technology platform

PRINCETON, N.J., July 28 /PRNewswire-FirstCall/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing novel products based on proven combinations of chemotherapeutic drugs, today announced that it raised in excess of $22.5 million in a Series C private equity financing.

All Series B investors participated in the financing and included; Domain Associates, Ventures West, Quaker BioVentures, TL Ventures, GrowthWorks Capital, and BDC Capital.

The proceeds will be used to fund Phase 2 studies of CPX-351 (a liposomal formulation of cytarabine:daunorubicin) in patients with acute myeloid leukemia. The company expects to start enrolling patients in a Phase 2 study of CPX-351 in newly diagnosed, elderly patients with AML before the end of 2008. Celator will continue to develop other CombiPlex(TM) products from its pipeline alone or in collaborations with pharmaceutical partners.

"This financing reflects the strong, continued support of our investors both in the company and our products," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "Our goal is to extend and enhance the lives of people with cancer. As a result, we have developed an oncology product pipeline that has significant commercial potential. These funds will allow us to conduct additional clinical trials and generate data that we believe will enable strategic partnerships with leading biotech and pharmaceutical companies."

Celator reported encouraging interim Phase 1 data with CPX-351 in December 2007 where complete remissions were obtained in patients with advanced leukemia. The company plans to submit additional CPX-351 pre-clinical and clinical data to this year's American Society of Hematology (ASH) meeting in December. In addition, positive Phase 2 clinical study results were reported for CPX-1
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
2. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
3. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Come fall, many children, teenagers, and ... they want to be for Halloween. And, a number ... decorative contact lenses bought without a prescription. ... people purchase and wear contact lenses without a prescription. ... ® consumer survey, 17 percent of Americans have ...
(Date:9/30/2014)... Sept. 30, 2014 Established and new ... distributors to help penetrate the growing Eastern European ... for a sales team and regional/local offices, reducing ... This is a crucial advantage as medical technology ... environment. New analysis from Frost & ...
(Date:9/30/2014)... -- China,s regulatory ... The country,s new leaders have recognized that the regulations ... far from perfect along with rapid population growth and ... council issued the latest "Regulations for the Supervision and ... it has come into force as June 1, 2014. ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 2Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 3Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 5
... announced today that CH live ... Measures (i.e. eMeasures).  CredenceHealth is the first real-time Clinical ... " CCHIT is pleased to be testing ... to offer these products to providers who wish to ...
... STEWARTVILLE, Minn., Jan. 12, 2011 Rochester Medical Corporation ... reached an agreement with Fornix N.V. to purchase from ... supplies distribution company located in Beuningen, The Netherlands.  Laprolan ... the Dutch market and had unaudited revenues of approximately ...
Cached Medicine Technology:CredenceHealth's CHlive Meaningful Use Certified (ONC-ATCB 2011/2012 Certification) 2CredenceHealth's CHlive Meaningful Use Certified (ONC-ATCB 2011/2012 Certification) 3Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V. 2Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V. 3
(Date:9/30/2014)... HealthDay Reporter MONDAY, Sept. ... medical implants -- artificial valves, hip replacements, surgical mesh and ... before or after their approval by the U.S. Food and ... conducted by prominent nonprofit groups and published online Sept. 29 ... for inadequate medical device testing on lax oversight by the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Houstonians seeking ... a place to visit on the Internet. Paul ... Houston’s most respected cosmetic surgeons, has launched a new ... the benefits of Botox Cosmetic services. The ... , According to the new website, Botox Cosmetic ...
(Date:9/30/2014)... September 30, 2014 Neuromuscular and ... throughout the United States and worldwide. It is ... are diagnosed each year, adding to the more ... disease. Approximately 400,000 people in the US are ... Add to these statistics the 2.4 percent of ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Farnoosh is now offering gum depigmentation treatments for dark ... but they can make people feel extremely self-conscious about ... treat discolored or dark gums. “I am one of ... lightening , and I have treated celebrities, business leaders, ...
(Date:9/30/2014)... Herceptin is the best drug treatment for a type ... standard of care for that type of tumor, according ... HER2-positive breast cancers tend to be more aggressive than ... Clinic. For the study, more than 8,300 patients ... (lapatinib) in addition to standard chemotherapy. After 4.5 ...
Breaking Medicine News(10 mins):Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2
... ... announced that nine distinguished scientists have joined its Environmental Task Force to explore possible ... IDA also announced the members of the Task Force’s Steering Committee as well as ... ...
... ... for military veterans harmed by Agent Orange. , ... Parkersburg, WV (PRWEB) April 24, 2010 -- According to attorney Jan ... and ischemic heart disease should have an easier time obtaining disability benefits under a recently ...
... for American adults have stabilized while the rate of childhood ... the journal Medical Decision Making , published by SAGE. ... from 2000-2004 and validated against 2005-2006 data, the study looked ... in the United States. The research explored statistics for many ...
... yielded best results when put in those younger ... News) -- Inserting cochlear implants early significantly improves ... who have severe hearing loss, a new study ... three years in 188 children who underwent cochlear ...
... to live together happily, experts say , FRIDAY, April 23 ... to cats, enduring regular bouts of congestion, sneezing, and watery ... as an office manager for a feline veterinary hospital in ... "They showed up and never left so I took them ...
... ... Research Council , low reimbursements from public health insurance programs, such as Medicare and Medicaid, ... forcing auto insurers to more closely scrutinize and negotiate hospital bills prior to payment. ... Malvern, PA (Vocus) April ...
Cached Medicine News:Health News:International Desalination Association Announces Members of Environmental Task Force and Dates for Environmental Symposium 2Health News:International Desalination Association Announces Members of Environmental Task Force and Dates for Environmental Symposium 3Health News:International Desalination Association Announces Members of Environmental Task Force and Dates for Environmental Symposium 4Health News:International Desalination Association Announces Members of Environmental Task Force and Dates for Environmental Symposium 5Health News:International Desalination Association Announces Members of Environmental Task Force and Dates for Environmental Symposium 6Health News:International Desalination Association Announces Members of Environmental Task Force and Dates for Environmental Symposium 7Health News:New Disability Benefits Could Soon Be Available to Vietnam Vets 2Health News:New Disability Benefits Could Soon Be Available to Vietnam Vets 3Health News:Early Surgery Best for Children With Hearing Loss 2Health News:Cat Allergy Doesn't Have to Mean Giving Up Kitty 2Health News:Cat Allergy Doesn't Have to Mean Giving Up Kitty 3Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 2Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 3Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 4
Ergonomic design and intuitive operations. Unique DOX digital SpO2 technology improves performance, even under the most challenging clinical conditions....
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
Medicine Products: